Horizon Investment Services LLC Takes $1.42 Million Position in Exelixis, Inc. $EXEL

Horizon Investment Services LLC purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 32,163 shares of the biotechnology company’s stock, valued at approximately $1,418,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Belpointe Asset Management LLC acquired a new stake in shares of Exelixis during the first quarter valued at about $572,000. D.A. Davidson & CO. purchased a new position in Exelixis in the second quarter valued at $212,000. Envestnet Asset Management Inc. grew its position in shares of Exelixis by 23.9% during the first quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company’s stock worth $9,159,000 after buying an additional 47,845 shares in the last quarter. Fortis Capital Advisors LLC acquired a new position in Exelixis during the 1st quarter worth approximately $572,000. Finally, Intech Investment Management LLC increased its holdings in Exelixis by 46.4% in the first quarter. Intech Investment Management LLC now owns 392,022 shares of the biotechnology company’s stock valued at $14,473,000 after buying an additional 124,297 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $40.80 on Friday. The stock’s 50-day simple moving average is $38.90 and its 200-day simple moving average is $40.31. Exelixis, Inc. has a 1 year low of $31.90 and a 1 year high of $49.62. The firm has a market cap of $10.98 billion, a price-to-earnings ratio of 19.62, a PEG ratio of 0.79 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.10. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm had revenue of $597.76 million during the quarter, compared to analyst estimates of $590.04 million. During the same quarter in the previous year, the firm earned $0.47 earnings per share. The firm’s revenue for the quarter was up 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. As a group, research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on EXEL shares. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Tuesday, July 29th. UBS Group lifted their price objective on shares of Exelixis from $35.00 to $40.00 and gave the company a “neutral” rating in a research report on Thursday. Cowen reissued a “buy” rating on shares of Exelixis in a research note on Wednesday. Stifel Nicolaus set a $43.00 price objective on shares of Exelixis in a report on Wednesday. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.45.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.